Search Within

Isabelle C Riviere

  1. "Bone Marrow Transplant"
  2. "Adult Leukemia"
  3. "Molecular Pharmacology and Chemistry Program Faculty"
  4. "Michel Sadelain"
Formats
  1. Meeting Abstract (18)
  2. Journal Article (6)
Groups
  1. Adult Leukemia (24)
  2. Bone Marrow Transplant (24)
  3. Center for Hematologic Malignancies (24)
  4. Department of Medicine (24)
  5. GSK Faculty (24)
  6. Hematologic Malignancies Research (24)

More Groups

People
  1. Michel Sadelain (24)
  2. Renier Brentjens (24)
  3. Jae Park (23)
  4. Kevin Curran (20)
  5. Craig Sauter (19)
  6. Xiuyan Wang (18)

More People

Years
  1. 2023 (2)
  2. 2022 (1)
  3. 2021 (1)
  4. 2020 (1)
  5. 2019 (2)
  6. 2018 (1)

More Years

Publications
  1. Blood (10)
  2. Molecular Therapy (3)
  3. Cancer Research (2)
  4. Journal of Clinical Oncology (2)
  5. Nature Medicine (2)
  6. Biology of Blood and Marrow Transplantation (1)

More Publications

Publishers
  1. American Society of Hematology (10)
  2. Nature Publishing Group (5)
  3. American Association for Cancer Research (2)
  4. American Society of Clinical Oncology (2)
  5. American Association for the Advancement of Science (1)
  6. Elsevier Inc. (1)

More Publishers

Results (24)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II trial of prophylactic anakinra to prevent neurotoxicity in patients receiving anti-CD19 CAR T-cell therapy for relapsed or refractory lymphoma: Final results from cohort 2
    Meeting Abstract

    Nath, K.; Devlin, S. M.; Sauter, C. S.; Palomba, M. L.; Shah, G. L.; Dahi, P. B.; Lin, R. J.; Scordo, M.; Perales, M. A.; Leslie, L. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: Phase 2 trial interim results
    Journal Article

    Park, J. H.; Nath, K.; Devlin, S. M.; Sauter, C. S.; Palomba, M. L.; Shah, G.; Dahi, P.; Lin, R. J.; Scordo, M.; Perales, M. A.; more...
    Nature Medicine (2023)

    Fulltext@MSK | Save
  • Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
    Journal Article

    Smith, M.; Dai, A.; Ghilardi, G.; Amelsberg, K. V.; Devlin, S. M.; Pajarillo, R.; Slingerland, J. B.; Beghi, S.; Herrera, P. S.; Giardina, P.; more...
    Nature Medicine (2022)

    Fulltext@MSK | Save
  • The intestinal microbiota correlates with response and toxicity after CAR T cell therapy in patients with B-cell malignancies
    Meeting Abstract

    Smith, M.; Dai, A.; Ghilardi, G.; Amelsberg, K.; Devlin, S. M.; Pajarillo, R.; Slingerland, J. B.; Beghi, S.; Herrera, P. S.; Giardina, P. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Durable remission following "off-the-shelf" chimeric antigen receptor (CAR) T-cells in patients with relapse/refractory (R/R) B-cell malignancies
    Meeting Abstract

    Curran, K. J.; Sauter, C. S.; Kernan, N. A.; Prockop, S. E.; Boulad, F.; Perales, M.; Giralt, S. A.; Riviere, I.; Wang, X.; Boelens, J. J.; more...
    Biology of Blood and Marrow Transplantation (2020)

    Fulltext@MSK | Save
  • Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL
    Journal Article

    Curran, K. J.; Margossian, S. P.; Kernan, N. A.; Silverman, L. B.; Williams, D. A.; Shukla, N.; Kobos, R.; Forlenza, C. J.; Steinherz, P.; Prockop, S.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma
    Journal Article

    Sauter, C. S.; Senechal, B.; Rivière, I.; Ni, A.; Bernal, Y.; Wang, X.; Purdon, T.; Hall, M.; Singh, A. N.; Szenes, V. Z.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia
    Journal Article

    Park, J. H.; Rivière, I.; Gonen, M.; Wang, X.; Sénéchal, B.; Curran, K. J.; Sauter, C.; Wang, Y.; Santomasso, B.; Mead, E.; more...
    New England Journal of Medicine (2018)

    Fulltext@MSK | Save
  • High dose cyclophosphamide and pre-treatment disease burden dictate response and survival in a multicenter clinical trial using CD19-specific CAR T cells for relapsed/refractory B-ALL
    Meeting Abstract

    Curran, K. J.; Margossian, S. P.; Kernan, N. A.; Silverman, L. B.; Park, J. H.; Sauter, C. S.; Smith, E. L.; Boulad, F.; Cancio, M. I.; Forlenza, C.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • A Phase I trial of 19-28z CAR-T cells post-high dose therapy and autologous transplantation (HDT-ASCT) for relapsed and refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL)
    Meeting Abstract

    Sauter, C.; Riviere, I.; Senechal, B.; Ni, A.; Bernal, Y.; Wang, X.; Purdon, T.; Hall, M.; Moskowitz, C.; Giralt, S.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save